NCT04904510 is a clinical trial of INDICAID™ COVID-19 Rapid Antigen Test in Covid19, sponsored by University of California, Los Angeles.

Who is sponsoring NCT04904510?

NCT04904510 is sponsored by University of California, Los Angeles.

What drugs are being tested in NCT04904510?

Interventions in NCT04904510: INDICAID™ COVID-19 Rapid Antigen Test.

Is NCT04904510 still recruiting?

NCT04904510 is currently completed. Last updated 15 February 2023.

Are results published for NCT04904510?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-02-15 · How we verify

NCT04904510

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the INDICAID™ COVID-19 Rapid Antigen Test

Completed Results posted Last updated 15 February 2023

What this trial tests

trial testing INDICAID™ COVID-19 Rapid Antigen Test in Covid19 in 297 participants. Completed in 9 March 2021.

Timeline

20 November 2020

Primary endpoint
9 March 2021

9 March 2021

Quick facts

Lead sponsor	University of California, Los Angeles
Status	Completed
Study type	OBSERVATIONAL
Enrollment	297
Start date	20 November 2020
Primary completion	9 March 2021
Estimated completion	9 March 2021
Sites	1 location across United States

Drugs / interventions tested

INDICAID™ COVID-19 Rapid Antigen Test

Conditions studied

Covid19 — all drugs for Covid19 →

Sponsor

University of California, Los Angeles

Who can join

5 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Test Concordance Primary · Day 1

The concordance with the INDICAID COVID-19 Rapid Antigen Test with an EUA PCR test

Group	Value	95% CI
Sample Collection	85.3	75.6 – 91.6

Sponsor's own description

The INDICAID™ Rapid Antigen Test was used in real-world outbreak testing. The antigen test was used together with PCR testing. This study was designed to evaluate whether the addition of a rapid antigen test decreased time to results in a real-world setting.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other University of California, Los Angeles trials

Trials by the same sponsor.

NCT04846517 — rTMS for Aneroxia Nervosa in Youth · NA · not yet recruiting
NCT06701760 — Sodium Lactate in Severe TBI · Phase 2 · not yet recruiting
NCT04996667 — Effect of iNO in Patients With Submassive and Massive PE · Phase 2 · withdrawn
NCT05067387 — Evaluation of Oral THC and CBD in Men and Women · Phase 1 · not yet recruiting
NCT07534696 — Evaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04904510 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Los Angeles
Last refreshed: 15 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04904510.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing